EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery of α-amylase and α-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach

Wilberforce Ndarawit, Charles Otieno Ochieng, David Angwenyi, Jorddy N Cruz, Cleydson B R Santos, Njogu M Kimani iD

PLOS ONE · 14.11.2024 · 19 (11) · e0313758

DOI: 10.1371/journal.pone.0313758 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, online erschienen am 14.11.2024. Verfasst von Wilberforce Ndarawit und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Physical Sciences, University of Embu, Embu, Kenya. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, alpha-Amylases, Glycoside Hydrolase Inhibitors, alpha-Glucosidases. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: International Foundation For Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Postprandial hyperglycemia, typical manifestation of Type 2 Diabetes Mellitus (T 2 DM), is associated with notable global morbidity and mortality. Preventing the advancement of this condition by delaying the rate of glucose absorption through inhibition of α-amylase and α-glucosidase enzymatic activities is of utmost importance. Finding a safe antidiabetic drug is essential since those that are currently on the market have drawbacks like unpleasant side effects. The current study utilized computer-aided drug design (CADD), as a quick and affordable method to find a substitute drug template that can be used to control postprandial hyperglycemia by modulating the activity of α-amylase and α-glucosidase enzymes. The Natural Products Activity and Species database (NPASS) (30,926 compounds) was screened in silico , with a focus on evaluating drug-likeness, toxicity profiles and ability to bind on a target protein. Two molecules NPC204580 (Chrotacumine C) and NPC137813 (1-O-(2-Methoxy-4-Acetylphenyl)-6-O-(E-Cinnamoyl)-Beta-D-Glucopyranoside) were identified as potential dual inhibitors for α-amylase and α-glucosidase with free binding energies of -14.46 kcal/mol and -12.58 kcal/mol for α-amylase, and -8.42 kcal/mol and -8.76 kcal/mol for α-glucosidase, respectively. The molecules showed ionic, H-bonding and hydrophobic interactions with critical amino acid residues of both enzymes. Moreover, 100 ns molecular dynamic simulations showed that both molecules are stable on the receptors’ active sites based on root mean square deviation (RMSD), root mean square fluctuation (RMSF), and the Generalized Born surface area (GBSA) energy calculated. The two compounds are thus promising therapeutic agents for T 2 DM that merit further investigation due to their excellent binding energies, encouraging pharmacokinetics, toxicity profiles, and stability as demonstrated in simulated studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2alpha-AmylasesGlycoside Hydrolase Inhibitorsalpha-GlucosidasesHumansHypoglycemic AgentsMolecular Docking SimulationCheminformaticsEnzyme InhibitorsMolecular Dynamics Simulation

Substanzen

alpha-AmylasesGlycoside Hydrolase Inhibitorsalpha-GlucosidasesHypoglycemic AgentsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Physical Sciences, University of Embu, Embu, Kenya.
  • Department of Chemistry, Maseno University, Maseno, Kenya.
  • Department of Mathematics, Masinde Muliro University of Science and Technology, Kakamega, Kenya.
  • Department of Biological Sciences and Health, Laboratory of Modeling and Computational Chemistry, Federal University of Amapá, Macapá, Amapá, Brazil.
  • Graduate Program in Medicinal Chemistry and Molecular Modelling, Health Science Institute, Federal University of Pará, Belém, PA, Brazil.
  • Natural Product Chemistry and Computational Drug Discovery Laboratory, Embu, Kenya.

ORCID-Profile: Njogu M Kimani

Förderung

  • International Foundation For Science

Zitieren

APA

Ndarawit, W., Ochieng, C. O., Angwenyi, D., Cruz, J. N., Santos, C. B. R., & Kimani, N. M. (2024). Discovery of α-amylase and α-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach. PLOS ONE, 19(11), e0313758. https://doi.org/10.1371/journal.pone.0313758

Vancouver

Ndarawit W, Ochieng CO, Angwenyi D, Cruz JN, Santos CBR, Kimani NM. Discovery of α-amylase and α-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach. PLOS ONE. 2024;19(11):e0313758. doi:10.1371/journal.pone.0313758

BibTeX
@article{Ndarawit2024,
  author = {Ndarawit, Wilberforce and Ochieng, Charles Otieno and Angwenyi, David and Cruz, Jorddy N and Santos, Cleydson B R and Kimani, Njogu M},
  title = {Discovery of α-amylase and α-glucosidase dual inhibitors from NPASS database for management of Type 2 Diabetes Mellitus: A chemoinformatic approach},
  journal = {PLOS ONE},
  year = {2024},
  volume = {19},
  number = {11},
  pages = {e0313758},
  doi = {10.1371/journal.pone.0313758}
}
Kostenlos starten →